Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02649556 · ClinicalTrials.gov registry record · NA

A 26-week Extension of the ZRHR-ERS-09-US Study Evaluating Biological and Functional Changes in Healthy Smokers After Switching to THS 2.2

A NA study of Smoking, sponsored by Philip Morris Products S.A..

Completed
Registry status
NA
Development phase
672
Enrollment target
19
Study locations

NCT02649556 is a NA study of Smoking that has completed, run by Philip Morris Products S.A.. The registered enrollment target is 672 participants, above the 450-participant average among 123 other Smoking trials with a reported enrollment target (49% higher). The trial reports 19 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02649556, a NA study of Smoking, has completed, sponsored by Philip Morris Products S.A..

COMPLETED
Registry status
NA
Development phase
672 participants
Enrollment target
19
Study locations

Study Summary

The objective of the ZRHR-ERS-09-EXT-US study is to further assess the effect of the Tobacco Heating System 2.2 (THS 2.2), a candidate Modified Risk Tobacco Product, compared to conventional cigarettes (CC) on the components of the "smokers' health profile" for a prolonged period of 26 weeks, providing additional information to the results of the original study ZRHR-ERS-09-US of 26-week exposure (NCT02396381). In total, the ZRHR-ERS-09-EXT-US study will extend the exposure period to 52 weeks.

Conditions Studied

Interventions

  • OTHER CC
  • OTHER THS 2.2

Study Locations (19)

Florida

  • Clinical Research West Florida - Clearwater
  • Covance, Inc - Daytona Beach
  • Compass Research - Orlando
  • Clinical Research West Florida - Tampa
  • Compass Research - The Villages

North Carolina

  • PMG Research of Cary - Cary
  • PMG Research of Charlotte - Charlotte
  • PMG Research of Raleigh - Raleigh
  • PMG Research of Wilmington - Wilmington

Texas

  • Benchmark - Austin
  • Benchmark - Fort Worth
  • Benchmark - San Angelo

Tennessee

  • PMG Research of Bristol - Bristol
  • NOCCR - Knoxville

Arizona

  • Celerion Arizona - Tempe

Kentucky

  • Central Kentucky Research Associate - Lexington

Nebraska

  • Celerion Lincoln - Lincoln

Ohio

  • Midwest Clinical Research - Dayton

Trial Details

FieldValue
Enrollment Target 672 participants
Start Date 2015-09-30
Est. Completion 2017-12-20
Phase NA

Sponsor

Philip Morris Products S.A.

11 total trials

What the Registry Record Tells You About NCT02649556

The ClinicalTrials.gov registry entry for NCT02649556 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 672 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 450-participant average among 123 other Smoking trials with a reported enrollment target (49% higher). The listed sponsor is Philip Morris Products S.A., which has 11 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Smoking appearing as the primary indexed condition, and to 2 interventions - of which CC is the first listed.

NCT02649556 reports 19 study locations spanning 9 distinct geographic areas - top geographies include Florida, North Carolina, Texas.

Frequently Asked Questions

What is clinical trial NCT02649556 about?

NCT02649556 is a clinical study titled "A 26-week Extension of the ZRHR-ERS-09-US Study Evaluating Biological and Functional Changes in Healthy Smokers After Switching to THS 2.2". The objective of the ZRHR-ERS-09-EXT-US study is to further assess the effect of the Tobacco Heating System 2.2 (THS 2.2), a candidate Modified Risk Tobacco Product, compared to conventional cigarettes (CC) on the components of the "smokers' health profile" for a prolonged period of 26 weeks, provid...

What is the current status of trial NCT02649556?

This trial is currently completed. It is a NA study. The enrollment target is 672 participants. The study started on 2015-09-30. Estimated completion is 2017-12-20.

What conditions does trial NCT02649556 study?

This clinical trial studies the following conditions: Smoking.

What interventions are being tested in trial NCT02649556?

The interventions under investigation include: CC (OTHER), THS 2.2 (OTHER).

Who is sponsoring clinical trial NCT02649556?

This trial is sponsored by Philip Morris Products S.A., which has 11 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02649556 being conducted?

This trial has 19 study locations across Arizona, Florida, Kentucky, Nebraska, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Smoking

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.